Introduction
Hyperthermia has been used for many years to treat a wide variety of tumors in both experimental animals and patients1'.
In Japan, the most commonly used heating method in clinical settings is capacitive heating using a radiofrequency (RF) electric field2). However, specifically heating tumors by capacitive heating using an RF electric field is difficult because the heating characteristics are influenced by various factors, such as tumor size, position of electrodes, and adhesion of electrodes at uneven sites.
Hyperthermia produced by heating mediators is a promising approach for specifically heating tumors without damaging normal tissues3)4). Previously, studies have examined inductive heating methods in which the heating mediators are sub-micron magnetic particles5-7). We have developed magnetite cationic liposomes (MCLs) as mediators of intracellular hyperthermia8-10). These cationic liposomes exhibit improved adsorption and accumulation in tumor cells, and have 10-fold higher affinity for tumor cells than neutrally charged magnetoliposomes8), thus suggesting that MCLs are superior mediators of hyperthermia. We previously demonstrated the efficacy of MCL-mediated hyperthermia in animals with several cell lines, including B16 mouse melanoma11), T-9 rat glioma9), 0s515 hamster osteosarcoma'2), MM46 mouse mammary carcinoma'3), PLS 10 rat prostate cancer11)), and VX-7 squamous cell carcinoma in rabbit tongue11)). Although MCL-mediated hyperthermia was found to be very effective for inducing complete tumor regression in transplantable tumor models, no studies have used a hereditary cancer model, which is thought to be good approximation of cancer patients.
To date, various types of transgenic mouse have been produced to investigate the function of oncogenes in the process of cell differentiation of cells in vivo16g7). The ret oncogene was activated by DNA rearrangement of the ret proto-oncogene with other cellular sequences during NIH3T3 transfection assay18)19). The ret proto-oncogene encodes a receptor-type tyrosine kinase and is often expressed in human cell lines or tumors of neuroectodermal origin, such as neuroblastoma, pheochromocytoma and thyroid medullary carcinoma2°-23). Previously, in order to further investigate the action of the ret protein in various tissues, the mouse metallothionein (MT)-I promoter, which is known to function in almost all tissues24), was used. Surprisingly, four independent transgenic lines showed hyperpigmented skin due to aberrant melanogenesis25), and the melanocytic tumor that developed in MT/ret transgenic mice of line 304 finally progressed to melanoma accompanied by distant metastasis26)27). In this transgenic mouse line, tumors developed mainly in the skin. An effective protocol for melanoma therapy is urgently needed because of the recent reduction in the Earth's ozone layer, which blocks the sun's ultraviolet rays28) and the increasing incidence of melanoma, which is occurring at a greater rate than that of any other cancer29). In addition, a relatively high percentage of melanoma is hereditary (6-14 %)30)31). In the present study, we assessed the feasibility and potential of MCL-mediated hyperthermia to treat hereditary melanoma in a MT / ret transgenic mouse line.
Materials and Methods

Preparation of MCLs
Magnetite particles were kindly donated by Toda Kogyo Co. (Hiroshima ; average particle size, 10 nm). MCLs were prepared using a previously described sonication method, with slight modification8).
Briefly, 1 ml of colloidal magnetite was coated with a lipid membrane consisting of This means that 4 mg of magnetite was sufficient to achieve a tumor temperature of 45°C. No serious burning on the skin was observed in these mice. In addition, rectal temperature increased only slightly during the irradiation, thus suggesting tumor-specific hyperthermia.
The therapeutic effects of RH of the melanoma nodules in MT / ret transgenic mice were then examined. A melanoma nodule with a size of 5-7 mm in diameter was injected with MCLs, and AMF irradiation was carried out three times at 24-h intervals. We previously reported that an iteration of RH was effective for malignant cancers (e.g. mouse mammary carcinoma of size > 15 mm)13) ; in the present study, this protocol was applied to MT I ret transgenic mice. Mice were treated with RH, as shown in Survival data for a period of 120 days after hyperthermia is shown in Fig. 4 . The tumors in MT I ret transgenic mice metastasize to the lymph nodes, lung, brain, kidney, liver, and spleen26). This distribution pattern of metastasis corresponds well to that in human skin malignant melanomas in which the lung and lymph nodes are the most common sites of distant metastasis33). In the present study, the lung was extirpated from all dead mice and examined for pulmonary metastases . In the control groups, all mice died within 60 d, and pulmonary metastases were observed in two of five mice. On the other hand, three of five mice in the hyperthermia group survived to 120 days, and significant prolongation of overall survival was observed compared with control group (p = 0.024).
Because multiple tumors (4.5 tumors on average) developed in the skin, the size of all tumors, including heated and non-heated tumors were measured. Previously, we observed a 'bystander effect' resulting from MCL-mediated hyperthermia in an experimental T-9 rat glioma model in which one tumor was transplanted into each femur of a rat ; although only one tumor was subjected to hyperthermia, the other tumor also disappeared completely34). In the present study, in order to investigate whether a bystander effects could be induced after RH in MT / ret transgenic mice, the sizes of all the tumors were measured. Representative data are shown in with sizes ranging from 2 to 8 mm, which were located in the back and tail. In the control mice, all tumors grew and no tumor regression was observed, as shown in Fig. 5A . In the hyperthermia group (Fig. 5B) on the other hand, although only one tumor (number 1 in Fig. 5B ) was treated twice with RH, the other three tumors (two on the back and one on the tail) also regressed and disappeared.
Discussion
In the case of superficial tumors, such as melanoma, a simple heat mediator is desirable for the clinical application of hyperthermia. However, it is difficult to heat a superficial tumor specifically with a capacitive heating method using an RF electric field. Microwave hyperthermia causes severe injury, because the temperature of the surrounding epidermic tissue becomes substantially higher than that of tumor tissue. We used MCLs in order to heat the tumoral region and minimize heating of surrounding healthy tissue. The results shown in Figure 1 suggest that hyperthermia using MCLs allows tumors to be heated specifically. Tumor temperature was maintained very precisely within a small standard deviation, thus demonstrating the ease of temperature control by manipulating the magnetic field intensity. We previously demonstrated the efficacy of hyperthermia using MCLs against animals having several types of tumor, including B16 mouse melanoma11). In these cases, our hyperthermia system could specifically generate heat at the tumor site with magnetite during AMF irradiation, and no heat was ( 17 ) class I and/or II antigens. The mechanism of these bystander effects in MT / ret transgenic mice is particularly important because MT / ret transgenic mice represent a hereditary cancer model that is thought to be good approximation of cancer patients, and we are now investigating the mechanism.
These results suggest that MCL-mediated hyperthermia is potentially effective for malignant melanoma, because in addition to directly killing tumors with heat, they induce a bystander effect on distant metastases.
In summary, the stable tumoral treatment temperatures, therapeutic effects, and survival benefits demonstrate the feasibility of RH using MCLs in a hereditary melanoma model. 
